Simple Summary During the development and progression of lung tumors, processes such
as necrosis and vascular invasion shed tumor cells or cellular components into various fluid …

Cancer is a molecular disease associated with alterations in the genome, which, thanks to
the highly improved sensitivity of mutation detection techniques, can be identified in cell-free …

Cancer treatment is evolving towards therapies targeted at specific molecular abnormalities
that drive tumor growth. Consequently, to determine which patients are eligible, accurate …

The analysis of cell-free circulating tumor DNA (ctDNA) is a very promising tool and might
revolutionize cancer care with respect to early detection, identification of minimal residual …

Circulating tumoral DNA (ctDNA), commonly named “liquid biopsy”, has emerged as a new
promising noninvasive tool to detect biomarker in several cancers including lung cancer …

Background Locally advanced NSCLC is one of the most heterogeneous conditions, with
multidimensional treatments involved. Neoadjuvant therapy had been commonly considered …

Measuring total cell-free DNA (cfDNA) or cancer-specific mutations herein has presented as
new tools in aiding the treatment of cancer patients. Studies show that total cfDNA bears …

Response evaluation for cancer treatment consists primarily of clinical and radiological
assessments. In addition, a limited number of serum biomarkers that assess treatment …

Peripheral circulating free DNA (cfDNA) is DNA that is detected in plasma or serum fluid with
a cell-free status. For cancer patients, cfDNA not only originates from apoptotic cells but also …

Objective Somatic TP53 mutation (TP53 mut) is a characteristic finding in high-grade serous
ovarian cancer (HGSOC). The aim of this study was to assess the clinical efficacy and utility …